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with multiple malignancies
 
To the Editor
 
A coincidence of cylindroma and trichoepithelioma was
described first by Friboes in 1912. The disease was named
Brooke–Spiegler syndrome or familial autosomal dominant
cylindromatosis (MacKusick catalogue, 123850, 313100;
OMIM numbers 123850, 132700, 313100 and 605041).
 
1,2
 
A 72-year old Caucasian man was referred to our dermatology
department because of a relapse of his long-standing psoriasis,
which had been treated repeatedly by the modified Ingram
scheme. He had a history of multiple cylindromas and spirade-
nomas of the scalp and trunk. Trichoepitheliomas on the face,
shoulder and trunk were surgically removed. In 1996 a
malignant cylindroma of the scalp was operated on. In the same
year multifocally growing basal cell adenocarcinomas of both
parotid glands were diagnosed and treated by combined
surgery and radiotherapy.
On examination, he presented with large disseminated
erythematosquamous plaques, Fitzpatrick skin type II–III. On
the trunk, multiple skin-coloured to reddish papules and
nodules were found. Small yellowish papules were seen in the
nasolabial fold and retroauricular. An exophytic nodule (3 cm
diameter) on the right flank was removed by surgery. Histological
examination revealed a cystic skin tumour with adnexal differ-
entiation. We found atypical enlarged cells with prominent
nuclei, partially irregular nuclear shapes and increased ductal
proliferation. Focally, there was a squamous differentiation
with infiltrative growth into the hyalinized and sclerotic con-
nective tissue (fig. 1). The diagnosis of spiradenoma with
malignant transformation was made. We investigated p53
expression using pronase-digested specimen. The tumour
expressed p53 as shown in fig. 2. Chest X-ray and ultrasound
investigation of the abdomen and lymph nodes did not provide
any evidence of metastatic spread.
The combination of cylindroma(s) with trichoepithelioma(s)
is characteristic for the Brooke–Spiegler syndrome. Less often,
spiradenomas develop.
 
1,2
 
 Malignant transformation of
sweat gland tumours of skin is rare. We found only 31 cases
of malignant cylindroma
 
2–5
 
 and 16 cases of malignant
spiradenoma
 
2,6–8
 
 reported in the literature. To the best of our
knowledge, malignant transformation of a spiradenoma has
not been reported before in Brooke–Spiegler syndrome.
The involvement of the parotid gland has occasionally been
observed.
 
2
 
 Basal cell adenomas are the most frequent parotid
tumours in association with Brooke–Spiegler syndrome, but
adenocarcinomas may also develop as in the present case.
The occurrence of several malignancies in the same patient is
remarkable. Based on investigative studies in skin adnexal
tumours and parotid gland tumours, p53 overexpression
occurs in about two-thirds of specimens.
 
9,10
 
 It was assumed
that UV light may play a role in the development of sweat gland
carcinomas.
 
9
 
 Indeed, the present patient was repeatedly
exposed to UV irradiation because of his coincident psoriasis.
On the other hand, we have demonstrated that the tumour
expressed p53 (fig. 2). UV-therapy of psoriasis may be considered
a risk factor for malignant transformation of adnexal skin
tumours in Brooke–Spiegler syndrome.
fig. 1 Histopathology of malignant spiradenoma: focally squamous differen-
tiation with infiltrative growth into the hyalinized and sclerotic connective
tissue (haematoxylin–eosin stain).
fig. 2 p53 expression in malignant spiradenoma (immunoperoxidase
staining).
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? 200418Letters
Cutaneous necrosis during paroxysmal 
nocturnal haemoglobinuria: role of 
 
parvovirus B19?
 
To the Editor
 
We report the case of a 70-year-old woman hospitalized in
January 2001 for the treatment of diffuse cutaneous necrosis.
She had a past history of myelodysplastic syndrome since 1988,
treated with prednisone and transfusions of red blood cells.
Twenty-four hours earlier, she had presented with a pseudo-
influenza syndrome followed by necrosis of the ear lobes (fig. 1)
and necrotic plaques involving the whole of the tegument, and
39.6 
 
°
 
C fever.
Laboratory analyses revealed anaemia (haemoglobin was 7 g/
dL) and a platelet count of 30 g/L. The Coombs’ test was
negative. The remainder of the analysis eliminated disseminated
intravascular coagulation, cryoglobulinaemia and a primary
antiphospholipid antibody syndrome. Cold agglutinin titre was
also negative.
Bacteriological cultures and virus serologies remain negative
except for parvovirus B19. Indeed, serology for parvovirus B9
showed acute infection (parvovirus B19 IgM was positive,
whereas parvovirus B19 IgG was initially negative and later
became positive) and there was presence of viral DNA on
polymerase chain reaction (PCR) in serum.
Cutaneous histology revealed thrombosis of the capillaries
of the superficial and median dermis with thrombotic and
necrotic vascularitis and vascular deposits of A, M and C3
immunoglobulin under direct immunofluorescence.
Corticosteroid therapy was initiated at the dose of 1 mg/kg, the
patient’s fever disappeared, the skin lesions improved and, despite
the loss of the ear lobes, the patient’s general state improved.
In June 2001, 6 months later, the patient was again hospitalized
because of haemolytic anaemia (haemoglobin was 6 g/dL,
reticulocytes were 273 g/L), there was lowered haptoglobin and
increased lactic dehydrogenase levels at 8180 IU/L (normal
fig. 1 Necrosis of the ear lobes in a 70-year-old woman hospitalized for the
treatment of diffuse cutaneous necrosis.
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210–400 IU/L). For the first time during her blood disease, she
had haemoglobinuria. There was no new cutaneous lesions.
The acid haemolysis test (Ham–Dacie test), not performed
before, was positive and there was a deficiency of proteins
attached to the cell membrane by a phosphatidylinositol link
(CD55 and CD59), measured by flow cytometry, which confirmed
the diagnosis of paroxysmal nocturnal haemoglobinuria (PNH),
13 years after pancytopenia had first been demonstrated.
Cutaneous lesions during PNH are known, but rare, and are
manifested by petechias, leg ulcers and haemorrhagic bullae
becoming necrotic and predominantly involving the soles of the
feet, the toes, the tip of the nose and the ears.
 
1
 
 Corticosteroids
appear to be the treatment of choice for such lesions.
 
2
 
 Skin
histology showing thrombosis of the dermal vessels, reveals
the thrombotic tendency of these patients, in whom venous,
peripheral or central thromboses are the principal complica-
tions. The pathogenesis is uncertain, but the increase in platelet
aggregability during this disease could be one explanation.
 
3
 
The infections are described as inducing attacks in PNH.
 
4
 
 In
our case, a parvovirus B19 primo-infection appears to have
been at the origin of the haemolysis.
In adults, symptomatic parvovirus B19 primo-infection may
include an influenzae-like syndrome concomitant to various cutane-
ous signs, such as classical ‘gloves and socks’ purpura or other
types of vasculitis giving an image of necrosing leucocytoclastic
vascularitis
 
5
 
 on cutaneous histology, but without thrombosis.
With regard to haematology, this is responsible for acute
episodes or erythroblastopenia in patients suffering from cor-
puscle haemolysis
 
6
 
 as is the case in our patient.
This study is interesting as it suggests a relationship between
parvovirus B19 and the occurrence of haemolytic attack in
PNH, and in the development of cutaneous necrosis during this
disease. We propose that parvovirus B19 serology be conducted
when confronted with cutaneous necrosis in patients suffering
from PNH, as this was never done in the observations reported
earlier.
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Sweet’s syndrome and polycythaemia vera
 
To the Editor
 
Sweet’s syndrome (SS) is thought to be a hypersensitivity
reaction characterized by the sudden onset of tender, dark red
or purple, raised skin plaques that usually occur on the face,
neck, chest and limbs, accompanied by fever, malaise and neu-
trophilic leucocytosis.
 
1
 
 The disease may be linked to haemato-
logical cancers such as acute myelomonocytic leukaemia.
 
2,3
 
 We
report an uncommon case of SS associated with polycythaemia
vera (PV). A 63-year-old female complained of a 2-week history
of fever (38.5 
 
°
 
C), malaise, anorexia and weight loss, as well as
a skin rash located on her upper back and legs. Her medical his-
tory included three outbreaks of SS in the past 14 years (in 1989,
1991 and 1999), all of them diagnosed in our department, that
responded to treatment with oral corticosteroids, malignancy
having been ruled out. Skin examination showed a symmetrical
asymptomatic eruption of reddish blue, firm and confluent
papules and plaques of varying size on her upper back (fig. 1)
and firm red nodules on her legs, particularly on the ankles and
pretibial aspects. No lymphadenopathy or splenomegaly was
found in a physical examination. The laboratory findings
revealed a white blood cell count of 12.6 
 
×
 
 10
 
3
 
/
 
µ
 
L with 73%
fig. 1 Reddish blue, firm and confluent papules and plaques of varying size
affecting the dorsal back.
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segmented forms. Her haemoglobin concentration was
17.8 g/dL (haematocrit 52.8%), total red blood cell volume
38.9 mL/kg, and thrombocyte count 47.6 
 
×
 
 10
 
4
 
/
 
µ
 
L. The erythrocyte
sedimentation rate was 1 mm/h. Bone marrow examination
showed triline age hyperplasia. An abdominal ultrasonogram
revealed homogeneous splenomegaly. A chest X-ray was nor-
mal. Histopathological examination of skin biopsy specimens
of the back and leg showed an intense papillary and middermal
infiltrate of polymorphonuclear leucocytes with leucocytoclasis,
but vasculitic changes were absent (fig. 2). After a diagnosis of
PV and SS, the patient was treated with prednisone, 30 mg/day,
tapering at 10 days, and healing occurred without scarring
within 4 weeks. The haematological disease was treated later
with oral hydroxyurea, 500 mg/day. At the 2-year follow-up, no
evidence of leukaemic conversion was found.
A variety of conditions have been clearly linked to SS
including malignancies in about 20% of published cases,
 
4,5
 
 most
commonly haematological cancers, and particularly acute
myeloblastic leukaemia.
 
3,4
 
 In cases associated with underlying
malignancy, males are affected as frequently as females, fever is
usually but not invariably present, while neutrophilia may be
absent. These cases may also have anaemia, cytopenias, more
severe cutaneous manifestation, oral mucous membrane par-
ticipation and extracutaneous involvement.
 
2–5
 
 To the best of
our knowledge, six cases of SS associated with PV have been
reported so far.
 
5–10
 
 In five cases, PV preceded the onset of SS by
many years. In the sixth patient, as in ours, the cutaneous
lesions occurred intermittently for years (range 4–13 years)
prior to the onset of the haematological disorder.
 
7
 
 Progression
to myelofibrosis was reported in two cases
 
6,7
 
 and an acute mye-
logenous blast crisis occurred in one patient,
 
9
 
 whereas in three
patients
 
5,8,10
 
 no progression or transformation to more aggres-
sive stages took place. Furukuwa 
 
et al
 
.
 
8
 
 suggest that the asso-
ciation of SS and PV may be analogous to that of pyoderma
gangrenosum and PV. Therefore, patients with SS or pyoderma
gangrenosum and PV should be carefully followed up, as the
disorder may be related to myeloid transformation or frank
leukaemia.
 
5,7–8
 
 Association of neutrophilic dermatosis and PV
seems to worsen the prognosis of the last one. We report a new
case of SS heralding the onset of PV. The appearance of skin
lesions typical of SS should prompt investigation for underlying
malignancy, particularly haematological, and patients with
an established myeloproliferative disorder should be carefully
followed up in order to rule out a leukaemic conversion.
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An unusual presentation of a common skin 
 
pathology at an uncommon site
 
To the Editor
 
An 81-year-old female was referred by her general practi-
tioner to the plastic surgery outpatient clinic with a 5-month
history of a growth in the left ear. The growth had been
fig. 2 Normal epidermis, intense neutrophilic infiltrate in the upper and mid-
dermis and leucocytoclasis (haematoxylin–eosin stain; original magnification
× 100).
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increasing in size for the past 2 months and was a cause of
concern for the patient. There was no past medical or family
history of note, and there had been no previous surgery around
the left auricular area. On examination, there was an area of skin
measuring 2 × 2.5 cm within the left concha with multiple
papular, nodular and pigmented lesions extending into the
external auditory meatus. This growth was of skin origin and
freely mobile over the underlying cartilage (fig. 1). There were
no palpable regional lymph nodes. An incisional biopsy was
carried out, the results of which were inconclusive. A decision was
made to perform an excisional biopsy of the lesion with split skin
graft to cover the defect. This was in view of the short history
and the diagnostic difficulty in excluding underlying skin
malignancy. Histopathological examination showed features of
irritated seborrhoeic keratosis with no evidence of malignancy.
Different types of benign and malignant neoplasms are
known to originate from the skin. Benign tumours can ori-
ginate from the epidermis, hair follicles, sebaceous glands and
sweat glands. Examples include seborrhoeic keratosis, keratoa-
canthoma, adenomas and papillomas among others. Clinically,
benign tumours are either slow growing or static, whereas
malignant tumours of the skin usually increase in size with time
and have a tendency to invade surrounding tissues. Common
skin cancers include basal and squamous cell carcinomas,
malignant melanoma, adnexal tumours and Kaposi’s sarcoma.
A number of premalignant conditions of the skin are also
known to undergo malignant change if left untreated, such as
solar keratosis and Bowen’s disease.
Seborrhoeic keratosis is one of the most common benign
neoplasms of the skin in adults. However, it rarely occurs on the
ear. Many factors have been suggested in the aetiology of this
disease, such as ultraviolet light exposure, human papillomavirus
infection, hereditary factors, action of oestrogen and other sex
hormones.1 The majority of clinically diagnosed seborrhoeic
keratoses are left untreated.
However, when diagnosis is in doubt material should be
taken for histological examination. Current methods include
shave biopsy and sharp curettage. In the above patient excision
biopsy was performed to exclude underlying skin malignancy such
as basal cell carcinoma, squamous cell carcinoma, etc. and to
obtain a histopathological diagnosis as this lesion had a short
history of rapid growth at an atypical site. Such a presentation
is not typical for a seborrhoeic keratosis as these are usually slow
growing and more common on areas of the skin exposed to sun.
fig. 1 (a) Growth within the concha of left ear. (b) Magnification showing its pigmented, raised, papular appearance.
4
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Clinically apparent seborrhoeic keratoses are known to
mimic skin neoplasms1,2 and the possibility of an association
between the two cannot be ruled out.1 Indeed there have been
reports of malignant transformation occurring in seborrhoeic
keratosis.3,4 Previous reports of auricular seborrhoeic keratoses
have described functional and diagnostic problems.5–7 Our
patient had an unusual presentation of a fast-growing, atypical-
looking lesion of the concha of the ear. An inconclusive in-
cisional biopsy necessitated the need for an excision biopsy,
which to our surprise showed seborrhoeic keratosis. Sebor-
rhoeic keratosis of the concha of the ear is very rare and it is thus
advised that full excision biopsy of conchal lesions should be
performed if an incisional biopsy is inconclusive.
A Tahir,* DS Murray
West Midlands Regional Plastic Surgery Unit, Selly Oak Hospital, 
Birmingham, UK. *Corresponding author, 72 Arosa Drive, Harborne, 
Birmingham, UK, BI7 0SE, tel. +121 4275642; 
fax ; E-mail: doctahir@doctors.org.uk
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Neurofibromatosis associated with 
psoriasis
To the Editor
Psoriasis and neurofibromatosis are both disorders that
probably have a strong genetic basis. Neurofibromatosis is an
autosomal dominantly inherited syndrome (except for type 5)
manifested by developmental changes in the nervous system,
bones and skin.1 It has an incidence of 1 : 3000–5000 and is seen
among all racial groups. The exact pathogenesis of the highly
variable features is not understood.2 Psoriasis is a common,
chronic and recurrent inflammatory disease of the skin. The
cause of psoriasis is still unknown. It is apparent that heredity
is of significance in some cases. Although genetic transmission
has not been clearly delineated.3
A 20-year-old woman with neurofibromatosis who
developed psoriasis bilaterally on the extremities presented
to our outpatient clinic (Department of Dermatology, Faculty
of Medicine, Dicle University, Diyarbakir, Turkey) for
treatment. She had suffered from psoriasis vulgaris for the
last 13 years. She had also noted the onset of skin nodules and
café-au-lait macules when she was 10 years old. No other
family members had a history of neurofibromatosis. Her family
history revealed that her brothers, age 10 and 27 years, had
psoriasis.
Dermatological examination revealed multiple cutaneous
neurofibromas and café-au-lait macules on the extremities, face
and trunk, a giant pigmented hairy naevi on the trunk (figs 1 and 2),
fig. 1 Multiple café-au-lait macules, cutaneous neurofibromas on the front of
body and bilateral psoriatic plaques on the knees.
4
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common efelid on the face and the freckles in the left axillary
area. Bilateral Lisch nodules were seen on ophthalmic examina-
tion. The psoriatic plaques were especially present bilaterally
on the knees and elbows (figs 1 and 2). She had pectus carinatus
on the chest. Histopathological examination of the psoriatic
lesion demonstrated the characteristic histological findings:
hyperkeratosis with parakeratosis, neutrophilic infiltrates
forming microabscesses into epidermis and dermal papillo-
matosis. A biopsy specimen from a cutaneous nodule demon-
strated the characteristic histopathological findings of a
cutaneous neurofibroma.
Routine laboratory and endocrinological investigations were
normal. Electroencephalography, abdominal ultrasonography,
magnetic resonance imaging (cranial) and X-ray of the head
showed no significant alteration. Topical calcipotriol 0.05%
ointment therapy for psoriatic lesions was begun twice daily,
and excellent improvement was obtained after 4 weeks.
Neurofibromatosis is a relatively common autosomal dominant
trait. A typical case is characterized by the presence of multiple
café-au-lait spots and soft fibrous tumours arising from nerve
sheaths that usually develop during childhood or adolescence.
Aside from typical cases, this disease has a variable expression.4
Several types have been described (types 1–7).1
Psoriasis and neurofibromatosis are both disorders that
probably have a strong genetic basis.5 The two disorders also
include the characteristic skin lesions. As it rare to see patients
having both disorders, a lack of direct relationship between
these two diseases has been suggested.5 In the past, there were
three reported cases in which neurofibromatosis and psoriasis
coexisted. In 1985, Roenigk and Manick5 reported a 57-year-old
man with neurofibromatosis type 1 and psoriasis. In 1990,
Nishimura and Hori4 reported a 58-year-old man with psoriasis
vulgaris. In the patient, neurofibromas had developed during
psoralen + ultraviolet A treatment. In 1999, Çelebi et al.6
reported a 7-year-old boy with neurofibromatosis who devel-
oped scalp psoriasis.
Our patient is a 20-year-old girl with neurofibromatosis and
psoriasis vulgaris. According to Riccardi’s7 classification, our
patient demonstrated neurofibromatosis type 1. No other family
members had a history of neurofibromatosis. Her brothers, age
10 and 27, both had psoriasis. We would expect this combination
to occur again in her family.
Most likely, this combination of psoriasis and neurofibroma-
tosis represents a chance event. The absence of reported cases
suggests that a direct relationship between these two diseases is
unlikely. Other reports of this combination would be of interest
and could be expected statistically.
M Arica,†* SA Erdal‡
†Department of Dermatology, Faculty of Medicine, Dicle University, 
Diyarbak•r, Turkey, ‡City Hospital, Diyarbak•r, Turkey. *Corresponding 
author, Mustafa Arica, Dicle University Faculty of Medicine, Department 
of Dermatology, 21280 Diyarbakir, Turkey, tel. +90 4122488001/4221; 
fax +90 4122488440; E-mail: mustafa2arica3@yahoo.co.uk
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Acute depression from isotretinoin. 
Another case
To the Editor
Psychological side-effects due to isotretinoin therapy have been
previously described, with particular emphasis on depression
and consequent suicide.1,2 Recent reports1–4 confirm ongoing
interest in this matter, which still remains controversial.
A 16-year-old male teenager was referred in January 2001
because of severe acne, which had been worsening over the last
3–4 months. The patient, a high school student and basketball
player, did not show any embarrassment about his unaesthetic
appearance, whereas his mother seemed to be particularly anx-
ious and worried. Systemic treatment with isotretinoin,
0.75 mg/kg per day, was started. Five weeks later, the patient
appeared to be fretful and beginning to complain about his
acne. Moreover, his mother reported an increased irritability
and a loss of concentration at school.
In the next 2 weeks, the situation came to a head. The mother
returned to our consultation saying that her son was terribly
depressed, often crying and frequently arguing with his parents.
The patient was immediately examined, and the presence of
pyogenic granuloma-like lesions on the cheeks confirmed that
there was no improvement in the acne; in addition, typical features
of major depression,5 including mood disturbances and behaviour
changes, were clearly detectable. Finally, the treatment was
discontinued and both mother and son were advised that psychotic
symptoms quickly disappear after discontinuing the isotretinoin.
Unfortunately, contact with them was lost after this episode.
Although several studies supported by Hoffmann-La Roche
have provided no evidence of a correlation between isotretinoin
therapy and psychiatric symptoms6–8 various cases of depres-
sion and a few cases of suicide or attempted suicide have been
reported over the last 15 years.1,3 I believe that the number of
reports of acute depression due to isotretinoin therapy are
widely underestimated. Many physicians, in fact, avoid a priori
the use of isotretinoin in a subset of patients considered predis-
posed to developing depression. Furthermore, some patients
under isotretinoin do not complete the treatment successfully, on
account of the appearance of hyperlipidaemia, myalgia or other
side-effects that may have preceded the psychiatric symptoms.
In conclusion, before the therapy the patient had no com-
plaints about the acne and no detectable psychiatric disorders,
but his mother was extremely concerned, and had decided to
consult a dermatologist and to start the therapy. It is quite likely
that he was probably susceptible to developing depression, and
that his mother’s anxiety in association with the isotretinoin
therapy had increased the depressive symptoms.
M La Placa*
Department of Clinical and Experimental Medicine, Dermatology 
Section, University of Bologna, Bologna, Italy. 
*Corresponding author, Department of Clinical and Experimental 
Medicine, Dermatology Section, University of Bologna, Via Massarenti, 
1, 40138 Bologna, Italy, tel. +39 051 341820; fax + 39 051 302744; 
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Are we starting to induce skin cancer in 
order to avoid topical steroids?
To the Editor
For the last couple of years topical tacrolimus has started to be
popular in treating atopic eczema. Its use has not been restricted
to specialists only but also extended to other specialities and to
general practitioners. It is stated by the manufacturer in the
pamphlet enclosed with the ointment that
Exposure of the skin to sunlight should be minimized and the
use of ultraviolet (UV) light from a solarium, therapy with
UVB or UVA in combination with psoralens (PUVA) should
be avoided during use of Protopic ointment. Physicians
should advise patients on appropriate sun protection
methods, such as minimization of the time in the sun, use of
a sunscreen product and covering of the skin with appropriate
clothing.1
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However, the main site currently treated with it is the face and
more seriously in children. To the best of our knowledge there
still many doctors who do not emphasize this risk to parents
before prescribing it to children. On the contrary, many parents
continue to expose their children to sunlight to add its ‘beneficial’
effect to that of topical tacrolimus.2
Moreover, the manufacturer stated in the same pamphlet that
In a photocarcinogenicity study, albino hairless mice
were chronically treated with tacrolimus ointment and UV
radiation. Animals treated with tacrolimus ointment showed
a statistically significant reduction in time to skin tumour
(squamous cell carcinoma) development and an increase in
the number of tumours. It is unclear whether the effect of
tacrolimus is due to systemic immunosuppression or a local
effect. The relevance of these findings for man is unknown.
However, the first author investigated this issue and proved that
topical tacrolimus did not only statistically increase the number
of tumours produced on the skin of CD-1 mice within 14 weeks3,4
(figs 1 and 2), but it also significantly decreased the CD4/CD8 ratio
in axillary and inguinal lymph nodes.2–4 This feature was associated
with unexpectedly higher tacrolimus concentration in the same
lymph nodes 6 weeks after application despite the fact its serum
concentration was 50–100-fold lower than when the drug is
systemically administered2 (Table 1). Homey et al. also found that
topical tacrolimus affects local immunity through decreasing the
CD25 expression on CD4+ cells in the local draining lymph nodes.5
The main reason for using topical tacrolimus so extensively is
that parents do not wish to use topical steroids especially on the
face of their children for a prolonged period in fear of develop-
ing irreversible steroid damage. However, it is well known that
weak steroids could be used safely for a longer period. We
wonder whether it is worth it to use an ointment that can induce
skin cancer on children’s faces just to avoid topical steroids in a
non-fatal condition such as atopic eczema.
On the other hand, we do not wish to lose the use of such an
effective therapy. To this end, we would like to make some
suggestions. We recommend:
• The manufacturer should emphasize the risks in children
more clearly.
• The use of topical tacrolimus should be restricted to specialists
only.
• The face and other exposed areas should be covered properly
by a suitable sun block whenever it is prescribed for these areas,
otherwise, the ointment should not be applied on these areas.
• Do more extensive research to indicate the maximum safe period
that we can use it for.
• At the moment we feel that it should not be used for more
than 12 weeks and to cover the areas treated with sun blocks
for the whole period of use and may be for a further 4 weeks.
• We do not know whether it would be safe to repeat the treatment
after the 12-week period or not, so we would not recommend
such practice until more information is available.
Y Niwa,†* I Nasr‡
†Niwa Institute for Immunology, Tosashimizu, Japan, ‡Royal Berkshire 
Hospital, Reading, UK. *Corresponding author, Niwa Institute for 
Immunology & Tosashimizu Hospital, 4-4 Asahimachi, Tosashimizu, 
Kochi 787-0303, Japan, tel. +81(0)880 82 2511; fax +81(0)880 82 4915; 
E-mail: yniwa@lime.ocn.ne.jp 
fig. 1 Squamous cell carcinoma that developed by week 15 in a mouse
treated with DMBA + tacrolimus without 12-O-tetradecanoylphorbol-13-
acetate (TPA).
fig. 2 Squamous cell carcinoma in situ (Bowen’s disease) or solar (actinic)
keratosis that developed by week 31 in ultraviolet light (UVL) irradiated-
mouse simultaneously applied with topical tacrolimus.
Table 1 Concentration of tacrolimus in inguinal and axillary lymph nodes 
after application of topical and systemic tacrolimus (performed in our 
laboratory, Niwa Institute for Immunology)
How to apply
Duration after application (weeks)
3 4 6 9
Oral uptake (0.3 µg daily) 5.9 5.6 5.3 5.3
Topical application (20 mg daily) 6.1 5.8 6.3 5.4
Tacrolimus concentration is expressed as ng per weight of minched lymph 
tissues.
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Effects of ultraviolet irradiation on mediator 
release from basophils and mast cells
To the Editor
We read with interest the manuscript by Monfrecola et al. about
the inhibiting and enhancing effects of ultraviolet (UV) A
irradiation on histamine release from human basophils.1 The
discussion gives a general overview about the human basophil
structure and physiology as well as interesting calculations
about circulating basophils as targets for natural or artificial
UVA irradiation; however, important information on the
effects of UV irradiation on mediator release from basophils
and mast cells is not considered. Early studies on natural
sunlight effects upon mast cell degranulation were published
decades ago followed by many studies on this topic. Experiments
with rat mast cells in the presence of photosen-sitizers (e.g.
protoporphyrin, acridine, pyrene, benoxaprofen, chlorpro-
mazine, chlortetracycline, 8-methoxypsoralen) showed a dual
effect (reduced mediator release at low UV doses, enhanced
release at high UV doses).2 A photo-basophil-histamine-release
test was introduced in 1987 by Przybilla et al. demonstrating
phototoxicity of non-steroidal anti-inflammatory drugs.3 In
addition, inhibiting effects of UVA irradiation in this test have
been reported by our group using UVA doses up to 100 J/cm2.4
Also, we defined the action spectrum of this effect with enriched
basophils (29% purity) showing inhibitory effects with UVA1
irradiation, but not with UVB irradiation.5 Furthermore, not
only anti-IgE, but also calcium-ionophore, FMLP, C5a in
basophils and compound 48/80, calcium-ionophore, substance
P and concanavalin A in mast cells were used as stimuli. More
data exist about the cell membrane as a possible target structure
for UVA-induced effects and other possible mechanisms,5 e.g.
increase in intracellular Ca+ levels or involvement of reactive
oxygen species.6
Besides in vitro measurements, several in vivo experiments
have shown inhibitory effects of UV irradiation on allergen,
anti-IgE, codeine phosphate or substance 48/80 induced weal
and flare reactions and itch in human skin as well as on sub-
stance 48/80 and concanavalin A induced ear swelling in mice
underlining similar mechanisms in vivo.7,8
We agree with the authors that studies on the differential
effects of UV irradiation on basophils and mast cells may add
useful information on pro- or anti-inflammatory effects of UV
on human health.
B Eberlein-König,* J Ring
Division ‘Environmental Dermatology and Allergology’ GSF/TUM, 
Neuherberg-Munich, Department of Dermatology and Allergy 
Biederstein, Technical University Munich, Germany, *Corresponding 
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Grover’s disease (transient acantholytic 
dermatosis) associated with atopy
To the Editor
Grover’s disease (transient acantholytic dermatosis) is a non-
immune acantholytic dermatosis, clinically characterized by
pruritic papules and vesicles, mainly distributed on the trunk,
that affects mostly adult males over 50 years old. In some cases
it has been reported in association with other systemic diseases.
We report a case of Grover’s disease in association with atopy
in a woman who was under 50 years old.
A 36-year-old woman was referred to the Department of
Biomedical and Surgical Sciences, Section of Dermatology
and Venereology (Verona University, Italy) in April 2002 after
experiencing onset of itchy papulovesicles and erosive lesions
in the abdominal region. These lesions were reported to have
been present for a month and had appeared spontaneously or
after minimal trauma. The patient reported that analogous
lesions had appeared on the trunk and abdominal region
6 months earlier and then spontaneously receded, except for the
persistence of hyperpigmentation.
Clinical examination revealed papulovesicles and erosive
plaques in the abdominal region, large from 3 to 20 cm (fig. 1).
Laboratory findings showed an atopic state, as demonstrated
by high levels of immunoglobulin E (627 KU/L), high levels of
eosinophilic cationic protein (31 µg/L) and RAST was positive
to some of the following: Poa pratensis > 100 kU/L; Cynodon
dactilon 31.3 kU/L; Parietaria officinalis 12 kU/L; Artemisia
vulgaris 6.3 kU/L; Ambrosia elatior 6.16 kU/L; Betulla 5.68 kU/
L; Olivo 5.58 kU/L. Other laboratory examinations were
normal.
A biopsy specimen was taken from the abdominal cutaneous
lesion. It revealed focal acantholysis in the spinosum layer,
associated with dyskeratosis, parakeratosis and neutrophilic
exocytosis with micropustules; in the dermis, under the der-
moepidermal junction and around the superficial and the deep
vascular plexus, there was a lymphohistiocytic infiltrate with
melanophages and neutrophilic granulocytes (fig. 2). Direct
immunofluorescence was negative.
Topical treatment with steroids and antibiotics led to clinical
resolution in 15–20 days, except for the persistence of pig-
mentary lesions. After 6 and 12 months of follow-up the patient
reported occasional onset of papulovesicles and erosive lesions,
which remitted after application of topical steroids. Grover’s
disease is a non-immune acantholytic disease, clinically charac-
terized by pruritic papules and papulovesicles, mainly distributed
on the trunk, occurring mostly in males, over 50 year old.
Histologically, the hallmark of the disease is focal acantholysis
in the epidermis, at a suprabasal or subcorneal level. Focal acan-
tholysis may present, in the same specimen, different forms
such as pemphigus-like, Hailey–Hailey disease-like, Darier’s
disease-like, and spongiotic. In the classical form of Grover’s
disease, cutaneous adnexa are not affected. Spongiosis, dyskera-
tosis and hypergranulosis also may be seen. A dermal inflam-
matory infiltrate, with lymphocytes, histiocytes and eosinophils
is often reported, and direct immunofluorescence is negative.1
The aetiology and pathogenesis of Grover’s disease is unknown.
Triggering factors have been identified in sweat, fever, heat and
sunlight. Some reports have hypothesized causation by poral
fig. 1 Papulovesicles and erosive plaques in the abdominal region with
hyperpigmentation in the resolution area.
fig. 2 Focal acantholysis in the spinosum layer, associated to dyskeratosis,
parakeratosis and neutrophilic exocytosis with micropustules (haematoxylin
and eosin, original magnification × 25).
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occlusion of damaged eccrine in intraepidermal ducts, with
spillage of sweat contents and focal acantholysis;2 otherwise,
acantholysis is often not associated with the eccrine duct outflow
tract.2 In our case, for example, acrosyringium was histologi-
cally intact. In Grover’s disease, different studies have shown the
primary damage in the proteins of the desmosomal attachment
plaque, such as desmoplakin I and II and plakoglobin;3 these
proteins, in fact, were seen dissolved and diffused into the
acantholytic cells.4
Grover’s disease has been reported in association with other
diseases. Davis et al. found a prevalence of association with mali-
gnant diseases in 25% of patients; neoplasms were both solid and
haematological.5,6 Other sporadic associations include human
immunodeficiency virus infections,5 chronic renal failure and
haemodialysis.7 In some cases an association with cutaneous
diseases has been found, even if it is not clear if the association
is casual. Grover’s disease, in fact, has been reported to occur
with scabies,8 pyoderma gangrenosum, asteatotic eczema and
allergic contact dermatitis.9
To the best of our knowledge, we have found one study in the
literature in which Grover’s disease is associated with atopic
dermatitis, and a Koebner phenomenon is postulated as the
pathogenetic mechanism.9
We presented this case for the onset of Grover’s disease in a
woman under 50 years old, and in association with an asympto-
matic atopic state; moreover, the onset of lesions was both post-
traumatic and spontaneous. We may hypothesize, however,
that the skin of our patient was more sensitive to irritative or
traumatic stimuli.
P Rosina,†* G Melzani,† M Marcelli,† W Zakaria,† C Colato,‡ A Barba†
†Department of Biomedical and Surgical Sciences, Section of Dermatology 
and Venereology, ‡Department of Pathologic Anatomy, Verona University, 
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Spitz naevus: a proposal for management
To the Editor
Spitz naevus is a clinical entity with clinical ambiguity that
makes the diagnosis and management of the patient difficult.
Much more is still to be learnt about its evolution, modifica-
tions seen clinically and by dermoscopy. Today, when a diagnosis
of Spitz naevus is made, the most common therapy is surgery.
We believe dermoscopy is a very useful method in the study
of Spitz naevi in order to understand its evolution, which until
now was unknown, and subsequently this will lead to better
management. We present our experience in the management of
Spitz naevi with a proposal of guidelines to differentiate Spitz
naevi to be asported and others to follow-up.
We report two cases of pigmented Spitz naevi that showed
morphological changes during the period of dermoscopic
follow-up.
Patient 1 is a 3-year-old boy with a pigmented, brownish
black papule (2.5 mm) on left knee. On dermoscopic evalu-
ation a globular pattern with brownish, black and light brownish
globules and a grey–blue pigmentation in the central area can
be recognized (fig. 1). During the second evaluation, a year later,
dermoscopic features were characterized by large brownish
globules with a reduction of the central grey–blue pigmentation
(fig. 2). At the third evaluation, 4 years later, clinically, the lesion
appeared as a pink reddish papule, and dermoscopic features
showed a reduction of globules and multiple fibrotic areas (fig. 3).
Patient 2 is an 11-year-old boy with a pigmented, black, very
small lesion (1.2 mm) on the right knee. Initially, dermoscopic
features were characterized by a globular pattern, associated
with a homogeneous central black area (fig. 4). At the second
evaluation 6 years later, the lesion was clinically smaller in size.
Dermoscopic features showed only a light brown reticular
pattern with a peripheral area that was more pigmented (fig. 5).
4
392 Letters
© 2005 European Academy of Dermatology and Venereology JEADV (2005) 19, 380–399
We would like to emphasize the uncertainty and difficulty
in the diagnosis and correct management of Spitz naevi.
There is no consensus about the benign nature of Spitz
naevi, but their natural history is not fully understood and the
histopathological differentiation is often as difficult as the
management.1
We are agreement with Kreusch et al.2 and Pizzichetta et al.3
in that there are various possible dermoscopic appearances of
Spitz naevi during their evolutionary phases, and are not always
in a globular or starburst pattern.
There are two extremes of management: Spitz naevus can be
always periodically controlled, or should be always excised. In a
recent article about the management of Spitz naevi, 93% of der-
matologists consulted recommended biopsies of ‘suspected’
Spitz naevus.4
In future we should hypothesize a dermoscopic follow-up for
Spitz naevi:
1 In children under 12 years follow-up every 6 months for the
first 2 or 3 years and then just once a year.
2 In children 12 years aged and over (i) follow-up every year for
lesions with typical clinical and dermoscopic features, and (ii)
surgical removal of all Spitz naevi with atypical clinical and
dermoscopic features.
fig. 1 Patient 1: dermoscopic evaluation at 3 years old: globular pattern with
brownish black and light brownish globules, and a grey–blue pigmentation
in the central area.
fig. 2 Patient 1: dermoscopic evaluation at 4 years old: large brownish glob-
ular with a reduction of central grey–blue pigmentation.
fig. 3 Patient 1: dermoscopic evaluation at 7 years old: reduction of globules
and multiple fibrotic areas.
fig. 4 Patient 2: dermoscopic evaluation at 11 years old: globular pattern,
associated with homogeneous central black area.
fig. 5 Patient 2: dermoscopic evaluation at 17 years old: light brown reticular
pattern with a peripheral area more pigmented.
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Topical immunotherapy with diphencyprone 
in the treatment of extensive and/or 
long-lasting alopecia areata
To the Editor
Alopecia areata (AA) is a common disease characterized by the
sudden and complete loss of hairs in a localized area of the body.
Diphencyprone (diphenylcyclopropenone, DPCP), which had
been known as a potent contact allergen since 1972, was first
reported as an effective treatment in AA in 1983.1 DPCP has
since been used extensively as contact sensitizer for AA.2–4
Although the mechanism of action of DPCP has not been clearly
defined, it has been proposed this immunogen recruits a different
T-cell subpopulation to the treated area, which in turn enhances
the clearance of the putative follicular antigen.5 Reported
response rates of DPCP are highly variable, ranging from 4% to
85%.6 A recent evidence-based review on the treatment of AA
concluded that immunotherapy with contact sensitizers is the
only approach that has proven effectiveness.7
This study was conducted to assess the efficacy of DPCP in the
treatment of AA, and to identify patient and treatment factors
related to therapeutic success. The study was approved by the
Institutional Review Board of the Center for Research and
Training in Skin Diseases and Leprosy. Fifty-six consenting
patients with chronic and/or extensive AA were selected. The
criteria for inclusion were the presence of extensive AA (loss of
more than 25% of scalp hair) and/or chronic AA (no hair
regrowth in more than a year). Grading of the disease was done
by AA investigational assessment guidelines.8 Table 1 shows the
characteristics of the study population. The preparation and
application of DPCP were similar to previous studies.2–4 The
overall duration of therapy was 4–48 months (mean ± SD,
12.7 ± 9.2 months).
At least 3 months after the initiation of the treatment, we
evaluated the patients based on their clinical response to treatment.
Hair regrowth was assessed according to the grading system
proposed by MacDonald Hull and Norris and grades of 3 and 4
were considered as ‘response to treatment’.4
Nine patients of 56 were treated for less than 3 months (and
excluded from analysis) due to lack of efficacy (n = 4), changing
their residence (n = 3), occurrence of side-effects (blister,
n = 1), and complete improvement of AA (n = 1). Response to
treatment was observed in 51.1% of the remaining patients (24
of 47). Duration of treatment was related to grade of response
(fig. 1). Other variables, including gender, age, grade of AA
(scalp, body or nail), age at onset of AA, total duration of AA,
Table 1 Characteristics of study population
 
Mean age (years) 23.8 ± 11.5
Male/female ratio 14/33
Mean age at onset of AA (years) 16.5 ± 8.9
Mean duration of current episode (years) 2.3 ± 2.0
Grade of AA* (%)
S1 6 (12.8)
S2 6 (12.8)
S3 6 (12.8)
S4 12 (25.6)
S5 17 (35.9)
Nail involvement (%) 26 (55.3)
Stress as the trigger (%) 22 (46.8)
Personal history of autoimmune disease (%) 14 (29.8)
Family history of autoimmune disease (%) 34 (72.2)
*The grading was based on alopecia areata (AA) investigational assessment 
guidelines.8
fig. 1 Duration of treatment in each grade of response (P < 0.001).
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duration of the current episode of AA, and personal or family
history of autoimmune diseases were not associated with
response to treatment.
In those patients who responded, the duration of treatment
to response achievement ranged between 2 and 30 months
(mean ± SD, 9.8 ± 7.2 months), and was not related to grade of
AA. Among these patients, five patients showed evidence of
relapse.
The response rate in this study seems to be similar to studies
reported by Wiseman et al. (50%),5 and van der Steen et al.
(50.4%).2 However, response rates to DPCP ranging from 4 to
85% have been reported.6 Presence of nail abnormalities, the
extent of alopecia, the duration of alopecia, age at onset of AA,
personal history of atopy have been considered as prognostic
factors in some previous studies,2,5,6,9,10 but we did not find
such relations. Possible explanations for this high degree of
inconsistency are the number of patients in the trials, variability
in immunotherapy protocols, treatment duration, follow-up
periods, and different methodological or reporting factors,
especially lack of a uniform definition for ‘response’. Any inter-
pretation of the efficacy of topical immunotherapy is further
limited by the fact that AA may clear by chance during a course
of treatment.
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Incontinentia pigmenti: a case with an 
unusual course
To the Editor
An 18-month-old girl presented with a 14-month history of
several recurrent erythematous, papular lesions with a linear
pattern. Typical vesicular lesions were not found. The lesions
affected extremities, and particularly the legs (fig. 1a). Each
recurrence was triggered by viral infections, either gastrointestinal
or rhinopharyngeal, always accompanied with fever. The
inflammatory lesions cleared in 45 days, leaving a discrete
hyperpigmentation. The mother declared that this phenomenon
reappeared in the same location each time her daughter had a
feverish infection. There were no lesions at birth. She had
partial anodontia (missing two upper incisors) and deformity
of two teeth, the same as her mother, but there were no signs of
associated malformations concerning the eyes or the central
nervous system. The mother had been born with erythematous
papules and vesicles on both arms and legs, and a clinical
diagnosis of incontinentia pigmenti (IP) had been made.
The diagnosis of IP was suggested by a familial history of IP,
the linear pattern of the lesions and their hyperpigmented evolu-
tion. The diagnosis was confirmed by histological examina-
tion of a skin biopsy specimen from a lesion on the thigh, which
showed epidermal acanthosis with numerous dyskeratotic cells
and focal ballooning of basal keratinocytes (fig. 1b). The upper
dermis showed lymphocytic and histiocytic inflammatory
infiltrates, both interstitial and perivascular. In addition,
foci of pigmentary incontinence, with numerous subepidermal
melanophages were also present.
The patient was followed for 2 years and no similar flares
were observed.
Our patient had IP according to diagnostic criteria defined by
Landy and Donnai.1 Classically, the skin lesions may occur at
birth, with four successive stages: erythema, then vesicles and
pustules (stage 1); verrucous lesions (stage 2); linear hyperpig-
mentation (stage 3); and pallor and scarring (stage 4). It is not
necessary for all stages to occur, and sometimes a number of
4
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stages overlap.1,2 They follow a linear pattern along the lines of
Blaschko, reflecting the somatic mosaicism due to the X chro-
mosome random inactivation in female patients.
Our case has some peculiar features relating to the cutaneous
course of IP. First, the delay in onset of the inflammatory stage.
The inflammatory skin changes of IP are usually present at birth
or develop within the first weeks. In only a few cases it has been
noted after the first 2 months. In a review of 310 cases of IP,
Carney2 found that, in 90% of cases, the eruption began within
2 weeks of birth, and in 96.4% of cases, eruptions began before
the patient was 6 weeks old. He found only eight patients in
whom, as in our case, the disease appeared between 6 and 52
weeks. Second, the recurrent inflammatory skin manifestations
along the hyperpigmented areas in combination with a feverish
infection is unusual. Until now, only a few cases of late re-
currences have been reported3–10 (Table 1). In most cases the
recurrence was preceded by fever and/or a viral infection, and
only one case appeared after laser treatment. No resurgence
of extracutaneous involvement was experienced in any of
these cutaneous exacerbations.
The mechanisms of these cutaneous reactivations still remain
unknown. The gene for IP has recently been identified in 85%
of cases, NEMO/IKKγ (Xq28), which encodes a regulatory
component of the IκB kinase complex, and whose alteration is
implicated in susceptibility to cellular apoptosis in response to
tumour necrosis factor-α.10 The mechanism of incontinence of
melanin in the skin might be the result of apoptosis of the IKKγ-
deficient cells. In a recent report Bodak et al.10 suggested the
possibility that this phenomenon of recurrence could be explained
by the persistence of some residual IKKγ-deficient cells, and
that some triggering factors, such as fever or infections, provoke
new flares of skin lesions, until the mutated cells are completely
eliminated. We agree with other authors that this atypical
presentation of IP, as in our case, is probably a more common
phenomenon, which may be mis/underdiagnosed; a statement
that should be tested in the future.
fig. 1 (a) Erythematous and papular lesions showing a linear distribution on the buttocks and legs. (b) Several dyskeratotic cells as focal pigmentary incon-
tinence, with melanophages, on the right (haematoxylin and eosin, original magnification × 100).
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Diffuse cutaneous eruption due to interferon 
alfa and ribavirin treatment of chronic 
hepatitis C
To the Editor
Interferon alfa and ribavirin combination, a selected treatment
option for chronic hepatitis C, has been reported to cause various
cutaneous changes.1 We present such a case who developed a
diffuse, pruritic eruption.
A 56-year-old man was first seen because of a pruritic eruption
of 1 week’s duration, which had started at the extremities and
had progressed to include his entire body. Examination revealed
erythematous and mildly oedematous 1–20 cm wide plaques
with no sharp borders. Lesions showed a tendency to coalesce
and were most prominent in the lower extremities and the
torso. A few plaques in the gluteal region and upper extremity
also had erosions and excoriations (fig. 1). The patient had been
diagnosed with hepatitis C 10 months prior to his cutaneous
complaints and had been started on ribavirin + interferon alfa
therapy 10 weeks ago. Laboratory work-up was normal except
for anaemia and leucopenia, which had emerged during
antiviral therapy and was accepted as an expected side-effect.
Hepatitis C virus RNA, which had been positive before therapy,
was negative this time. A lesional biopsy showed mild
psoriasiform hyperplasia and a mixed inflammatory reaction
consisting of perivascular eosinophils and lymphocytes.
Immunofluorescent examination showed only scattered and
Table 1 Review of the clinicopathological characteristics of recurrent episodes of IP in the literature
 
Cases
Skin 
lesions 
at birth
Associate 
alterations
Number and 
age of recurrence 
(month or year)
Predisposing 
factors
Clinical 
Stage of 
recurrence
Pathological 
stage of 
recurrence
Barnes3 1978 No Teeth Several episodes between 2 m and 18 y _ 1 2
Bessems4 1988 Yes Teeth/alopecia 3 episodes 2 y; 11 y; 20 y _ 1-2-3 2
Sahn5 1994 Yes Teeth Several episodes between 1 m and 12 m _ 1 1
Pfau6 1995 Yes No Several episodes between 1 m and 7 y Infection/fever 1–2 2
De Argila7 1996 No SNC (white substance) Several episodes between 2 m and 18 m _ 1 1
Nagasse8 1997 Yes No 1 episode 3 y Ruby laser 1 1
Van Leeuwen9 2000 Yes No 1 episode 8 m _ 1 _
Bodak10
N1 2003 Yes Retinal vasculopathy Several episodes between 9 m and 18 m Infection 1 _
N2 2003 Yes No Several episodes between 9 m and 12 m Fever 2 _
N3 2003 No No 1 episode 7 m Fever 1–2 2
N4 2003 Yes Convulsions 6 episodes between 4 m and 11 m Infection/not fever 1 _
N5 2003 Yes No Several episodes between 6 m and 7 y Fever 1 _
Our case No Teeth 4 episodes between 4 m and 18 m Infection/fever 1–2 2
4
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perivascular fibrinogen. Patch testing with the standard series
revealed no positive reactions. He was started on antihistamines
and a topical corticosteroid. Two weeks later, there was no
regression and facial involvement was more prominent. A
repeat biopsy showed hyperkeratosis, marked acanthosis, focal
spongiosis, exocytosis and dermal oedema with a moderate
mononuclear inflammatory infiltrate. Topical treatment was
switched to a more potent corticosteroid and a second
antihistamine. Then the patient was seen at bi-weekly intervals
but did not show any improvement except for less pruritus until
the end of the second month of the eruption. At this time, which
was the 18th week of antiviral therapy, there was an
intermission of hepatitis C treatment due to nose bleeds.
Interferon alfa was stopped for 1 week and ribavirin for
3 weeks. Rapid regression of the plaques into diffuse
hyperpigmentation and fine desquamation was observed
during this interval, especially after cessation of ribavirin
(fig. 2). Fifteen days after restarting ribavirin therapy the
patient was seen again for mild pruritus and similar plaques,
mainly on the lower half of the body. From then he was followed
with the same topical treatment for 10 weeks until these lesions
also regressed by hyperpigmentation.
Among reported cutaneous side-effects of ribavirin and
interferon alfa combination therapy are alopecia, herpes, lichen
planus, photoallergic eczema, hyperpigmentation, erythema
and/or induration at the injection site and a transient
generalized rash.1–4 The most extensive series with diffuse
inflammatory lesions has been reported by Dereure et al., who
in 20 patients observed eczema-like skin lesions mainly on the
extremities and sometimes associated with photosensitivity.
Initial appearance was between the second and fourth months;
histopathology revealed a perivascular lymphocytic infiltrate
and skin testing was not informative.5 Our patient’s clinical
history, morphology and distribution of lesions were similar
to the ones reported by Dereure et al. In contrast to another
report on patients with a diffuse eruption following
administration of only interferon alfa, our patient’s cutaneous
changes appeared later and took longer than 2 weeks to
disappear.6 Rapid regression of lesions following intermis-
sion of antiviral treatment coupled with the relapse when
medication was restarted served as a challenge test in our
patient. The fact that hepatitis C virus RNA, positive before
therapy, was negative all throughout the eruption also helps us
incriminate the interferon alfa and ribavirin combination and
not hepatitis C virus as the culprit that caused the cutaneous
symptoms.
E Savk,*† G Uslu,† AÖ Karaoglu‡ N Sendur,† G Karaman†
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fig. 1 Erythematous and mildly oedematous plaques with no sharp borders and
a tendency to coalesce most prominently in the lower extremities and the torso.
fig. 2 Regression of lesions into diffuse hyperpigmentation and fine
desquamation.
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Has Helicobacter pylori eradication therapy 
any effect on severity of rosacea symptoms?
To the Editor
Rosacea is a relatively common cutaneous vascular disorder
with a wide spectrum of clinical manifestations. Genetic dis-
position, gastrointestinal disturbances, Demodex folliculorum
mites, hypertension and psychogenic factors have been attributed
as causes of this disease, but the aetiology still remains to be
identified.
The role of Helicobacter pylori in rosacea has been an area of
interest after the presentation of a higher prevalence of H. pylori
infection in patients with rosacea than in the general Italian
population by Rebora et al.1 in 1994. Then, the possible aetio-
logical role of H. pylori in rosacea has been investigated in several
clinical trials.2–5 Taking into consideration the contradictory
results on rosacea and the infection of H. pylori, we undertook
a study in which we investigated the prevalence of H. pylori in
rosacea and the effect of eradication therapy for H. pylori infec-
tion on the severity of the rosacea symptoms. Our study popu-
lation consisted of 39 patients with clinically and histologically
proven rosacea. The severity of the disease was staged based on
the criteria which was described by Plewing and Jansen6 Follow-
ing the diagnosis and staging of the disease, presence/absence of
H. pylori infection was investigated by 14C urea breath in our
nuclear medicine department. The Heliprobe urea breath test
(Heliprobe, Noster System AB, Stockholm, Sweden), a recently
introduced dry system, was used as the 14C urea breath test fol-
lowing 6 h fasting. Rosacea patients with H. pylori infection
were assigned to the treatment group and were given a triple
regimen consisting of amoxicillin 1000 mg (two times a day),
clarithromycin 500 mg (two times a day) and lansoprazole 30 mg
(two times a day), orally for 2 weeks. During the time of H. pylori
eradication therapy, no other treatment for rosacea was given.
At the end of treatment (at the final clinical follow-up) each
patient underwent a follow-up 14C urea breath test to reveal
whether the infection was successfully eradicated or not. The
clinical evaluation was done three times for each patient: at
baseline (day 0: the time of diagnosis), at the end of therapy (day
14) and at the final clinical follow-up (day 60). All measure-
ments were done by the same dermatologist using the same
staging criteria and the efficacy measurement of H. pylori eradica-
tion therapy was made comparing the findings of baseline and
final (60th day) clinical evaluation. Follow-up clinical evalu-
ations were labelled as ‘partial remission’ (decrease in the stage
compared with basal evaluation), ‘no change’(remaining in the
same stage compared with basal evaluation) and ‘total remis-
sion’ (disappearing of symptoms). The distribution of rosacea
staging and H. pylori positivity at presentation are summarized
in Table 1. Comparison of basal and final clinical evaluation
(60th day) revealed that 13 of 20 (65%) patients in whom H.
pylori was successfully eradicated, had no change and seven of
20 (35%) had some improvement in the severity of symptoms.
Three of four patients (75%) with persistent H. pylori positivity
following the eradication therapy had no change, while one of
four (25%) had partial remission in the severity of rosacea
symptoms (Table 2). In terms of partial remission, there was no
statistically significant difference between the patients who had
H. pylori at the end of the treatment and who were eradicated.
(Table 2, Fisher’s Exact Test, P = 0.593). Twenty-six of 39 (66.6%)
rosacea patients had H. pylori infection and the remaining 13
(33.4%) were negative for the organism. It was shown by 14C
urea breath test that in 20 of 24 patients (83.3%) H. pylori infec-
tion was successfully eradicated. Among those 20 patients, only
less than half of the patients (seven of 20; 35%) had some clinical
improvement in rosacea symptoms and the majority of patients
(13 of 20; 65%) had no change in the severity of the disease in
spite of the fact that H. pylori was successfully eradicated. The
above findings led us to think that there is no clear beneficial
effect of H. pylori eradication on rosacea symptoms in con-
cordance with the results of the studies by Herr and You4 and
Bamford et al.5 There have been contradictory reports regarding
the question of whether prevalence of H. pylori infection is higher
than non-rosacea patients. In this presented study consisting of
39 rosacea patients we found the prevalence of H. pylori infec-
tion to be 66.6% using 14C urea breath test. We did not have our
own control group for comparison, but the prevalence of H.
pylori infection in non-rosacea patients in our hospital has been
previously reported to be 60% using the 13C urea breath test,
which is very similar to patients with rosacea in our study.7
Therefore, it can be thought that the prevalence of H. pylori is
similar to those of non-rosacea patients in our population,
which is disconcordant with the other studies.1,8,9
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Lack of control group is the limitation of our study. But it can
be concluded that improvement in rosacea following eradication
therapy for H. pylori seems unlikely to be due to eradication
of H. pylori.
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Table 1 Characteristics of 39 rosacea patients
Patient 
no.
Age, 
sex
Result of 
14C urea 
breath test
Clinical staging of rosacea
H. pylori 
eradication 
therapy†
Baseline 
(day 0)
First 
evaluation 
(day 14)
Final 
evaluation 
(day 60)
1 58, M + 3 1 1 Successful
2 53, M + 2 1 1 Successful
3 40, F + 2 1 1 Failed
4 51, M + 2 1 1 Successful
5 55, M + 2 1 1 Successful
6 49, F + 1 0 0 Successful
7 44, F + 2 1 1 Successful
8 53, F + 2 2 2 Successful
9 61, F + 2 1 2 Successful
10 49, F + 2 2 2 Successful
11 48, M + 2 1 2 Failed
12 43, F + 2 1 2 Failed
13 49, F + 2 1 2 Successful
14 62, M + 2 2 2 Successful
15 45, F + 3 3 3 Successful
16 63, F + 3 1 3 Successful
17 44, F + 2 2 2 Successful
18 39, M + 3 1 3 Successful
19 57, F + 2 2 2 Successful
20 48, F + 2 2 2 Failed
21 52, F + 2 2 2 Successful
22 46, M + 1 1 1 Successful
23 34, F + 2 1 2 Successful
24 40, M + 2 1 1 Successful
25* 50, F + 2 Not done
26* 50, M + 2 Not done
27 43, F – 1 Not done
28 44, F – 3 Not done
29 40, F – 1 Not done
30 55, F – 2 Not done
31 55, M – 2 Not done
32 20, F – 2 Not done
33 33, M – 2 Not done
34 62, F – 3 Not done
35 65, M – 2 Not done
36 41, F – 2 Not done
37 66, F – 1 Not done
38 54, M – 3 Not done
39 45, M – 2 Not done
*The patients refusing the eradication therapy for H. pylori.
†Determined by14C urea breath test.
Table 2 Improvement of rosacea symptoms after H. pylori eradication
 
Result of 14C urea 
breath test
Partial 
remission
No 
change
Total 
remission Total
H. pylori+ 1 3 0 4
H. pylori– 7 13 0 20
Total 8 16 0 24
P = 0.593, > 0.05. Fisher’s Exact Test.
